logo
Common vaginal condition is really an STD, study finds

Common vaginal condition is really an STD, study finds

CNN05-03-2025

A common but potentially dangerous vaginal infection that affects nearly 1 in 3 women globally should be considered a sexually transmitted disease, a new study says.
Bacterial vaginosis, or BV, is currently viewed as a woman's issue, thus leaving the sexual partner untreated.
'I started getting them quite recurrently. I'd go to doctors and get treated with antibiotics, and it would almost always come back,' said Hanae, a woman who participated in the clinical trial on BV conducted in Melbourne, Australia.
'It's like not really worth it for me to even go to doctors,' said Hanae, whose last name was withheld by the study authors to protect her privacy.
For half of all women with bacterial vaginosis, the infection returns after completion of a week of antibiotics, the preferred medical treatment for BV, said first author Lenka Vodstrcil, a senior research fellow at the Melbourne Sexual Health Centre at Monash University in Australia.
'The bacteria that cause BV can be located in men, especially in penile skin and also in the urethra,' Vodstrcil said in a news release. 'This suggests that BV is probably sexually transmitted, and that is why so many women get it back again after treatment.'
When BV was treated as a sexually transmitted disease, with both partners receiving oral antibiotics and men using topical creams, the recurrence rate dropped by over half, according to the study published Wednesday in the New England Journal of Medicine.
'Our trial has shown that reinfection from partners is causing a lot of the BV recurrence women experience, and provides evidence that BV is in fact a STI (sexually transmitted infection),' said senior author Catriona Bradshaw in an email. Bradshaw is a professor at the Melbourne Sexual Health Centre at Monash University.
A potentially dangerous infection
Symptoms of BV can include itching, pain while urinating, an odd odor and a thin, white vaginal discharge. For some women, however, BV is a silent predator, attacking without such telltale symptoms.
If left untreated, bacterial vaginosis can increase the risk of acquiring HIV as well as sexually transmitted infections, according to the World Health Organization. Women with BV can also develop an infection in the fallopian tubes, ovaries or uterus called pelvic inflammatory disease, the WHO states on its website.
Such infections can lead to later infertility, experts say.
'We see very significant changes in a range of inflammatory markers, inflammatory cells and bacterial enzymes and products that result in damage to the epithelium — the lining of the reproductive tract,' Bradshaw said.
Bacterial vaginosis is especially dangerous during pregnancy. The infection can lead to premature birth, spontaneous abortion and low birth weight in the baby, according to the WHO.
It's time for a 'paradigm shift' in treatment
The randomized clinical trial of 164 monogamous couples was conducted at multiple centers in Australia. In 81 of the couples, both partners were treated with seven days of oral antibiotics. During that time, the male partner also used a topical antibiotic on their penis twice a day.
In accordance with current recommended treatment, only the woman in the other 83 couples was treated with an oral antibiotic.
While the study only treated heterosexual couples, it's 'important to note that women in same sex relationships also transmit BV bacteria between each other during sex, and that these same sex couples in monogamous relationships have very high rates of concordance for BV — both have it or both don't have it,' Bradshaw said.
The trial was meant to last for 12 weeks, but researchers stopped it early when it was quickly apparent that treating both partners reduced BV occurrence by 60%.
Viewing such a common vaginal infection as a sexually transmitted disease would be a 'paradigm shift' and would require doctors to encourage a woman's male partner to share responsibility for transmission and treatment, according to an editorial published alongside the study.
'It will also require a willingness of male partners to commit to taking both oral and topical medications, once notified by their female partner that she has bacterial vaginosis and that it is probably sexually transmitted,' wrote Dr. Christina Muzny and Dr. Jack Sobel, who were not involved in the new research.
Muzny is a professor of infectious disease at the University of Alabama at Birmingham. Sobel is a professor in the Division of Infectious Diseases at the Wayne State University School of Medicine in Detroit.
Men in the study had no problem completing the course of oral and topical antibiotics, with few to no side effects, the study found.
'We have now used this medication in close to 300 men and we have not had any report that side effects from the medication would stop them taking it,' Bradshaw said.
The Melbourne Sexual Health Centre has already changed its protocols and are now treating both partners when BV is detected, Bradshaw added. For health professionals and couples interested in treating both partners, the research team is developing a website that provides detailed information on male partner treatment.
'Changes in national and international treatment guidelines always take time, so we felt an obligation to provide accurate online and downloadable information,' Bradshaw said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Matthew 25 unveils mobile STD testing unit
Matthew 25 unveils mobile STD testing unit

Yahoo

time2 hours ago

  • Yahoo

Matthew 25 unveils mobile STD testing unit

HENDERSON, Ky (WEHT) – The non-profit organization Matthew 25 held a ribbon cutting to celebrate its campaign to help prevent, educate and treat people in the Tri-State with Sexual Transmitted Diseases. Last August, The Centers for Disease Control and Prevention granted $3,000,000 in funding to the organization. Matthew 25 used a large portion of that grant in partnership with Mission Mobile Medical to customize the treatment center. As for why this was needed, Chief Executive Officer, Courtney Woolfork, said, 'We have clinics in Owensboro, Henderson, and Bowling Green. But everything in between is really hard for people to get access to, because there isn't public transportation always.' The non-profit covers 25 counties in Kentucky and 12 in Indiana and officials say that they have seen STD trends increasing in those regions. Woolfork says that trends like these are why it's so beneficial to have a mobile treatment unit that can serve vulnerable areas. The mobile unit will also have PREP pills available to those who have had a Sexually Transmitted Illnesses. Matthew 25 urges those who have come in contact with an STD or STI to get this pill to lessen their chances of contracting HIV in the future. Over the next couple months, Woolfork and her team plan on traveling to 25 counties in the Tri-State. March 27 will kick off the road trip, as they will be in Owensboro, Kentucky for National HIV Testing Day. Although they are fighting an uphill battle the mission statement is clear, 'Meeting people where they are and however they are.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Fast Five Quiz: Diffuse Large B-Cell Lymphoma
Fast Five Quiz: Diffuse Large B-Cell Lymphoma

Medscape

time5 hours ago

  • Medscape

Fast Five Quiz: Diffuse Large B-Cell Lymphoma

Although diffuse large B-cell lymphoma (DLBCL) is characterized by aggressive clinical behavior, standard treatment can provide good long-term survival outcomes. However, management can be complex, with certain comorbidities exacerbating disease severity and complications such as extranodal involvement significantly affecting prognosis. Understanding the nuances of DLCBL presentation, diagnosis, and management is key to delivering the best outcomes to patients affected by this rapidly progressive disease. What do you know about DLBCL? Check your knowledge with this quick quiz. Both primary and secondary Sjögren syndrome are strongly associated DLBCL. Other autoimmune disorders that have been associated with DLBCL include hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease. In addition to autoimmune disorders, viral infections have also been linked to DLBCL; these include HIV, hepatitis B, hepatitis C, and Epstein-Barr. Further, data have shown that patients with rheumatic diseases have a heightened risk of DLBCL development. Though fugal or bacterial pneumonia, humoral deficiency, and bone infections (such as osteomyelitis) can occur in patients with DLBCL, data have indicated that survivors of DLBCL were more likely to experience these conditions, rather than being strongly linked to DLBCL itself. Learn more about DLBCL staging. In the NCCN's guidelines, PET/CT is the preferred modality for imaging in DLBCL workup. C/A/P CT with contrast can also be used in a complementary setting to help stage the disease and identify other factors such as extranodal disease or visceral involvement, but it is not preferred. Although not essential, head CT/MRI or neck CT/MRI with contrast (as well as bone marrow biopsy) can be useful for workup in selected cases. Specifically, bone marrow biopsy can be helpful in identifying indolent or low-volume disease. However, the NCCN notes that bone marrow biopsy is not needed if PET/CT shows bone disease. Learn more about DLBCL workup. Data indicate that extranodal involvement occurs in approximately 30%– 50% of patients with DLBCL; further, it is reported that gastrointestinal involvement is the most common extranodal site. Other affected sites include the skin, bones, spleen, and central nervous system; kidneys, testicles, and the liver can also be impacted, but they are not regarded as the most common. Learn more about DLCBL and extranodal involvement. A population-based study involving over 30,000 patients with extranodal DLBCL found that the best outcomes are associated with heart and mediastinal sites, with a 42% reduction in mortality risk compared with involvement of the intestinal tract. Involvement of the pancreas and hepatobiliary system, respiratory system, or nervous system are associated with significantly greater risks of mortality compared with the intestinal tract. Other factors associated with greater mortality risk include late age at onset, history of other malignancy, late age at presentation, and Black, non-Hispanic ethnicity. Learn more about DLBCL prognosis. CAR T therapy is typically utilized as a second-line treatment for patients with relapsed/refractory DLBCL. CD19-directed CAR T-cell therapy is considered ' the standard of care' for relapsed/refractory DLBCL, with three treatments approved for this population. Although a number of factors can lead to CAR T cell therapy resistance, the key mechanism is typically down regulation or loss of CD19 expression. Abnormal differentiation and dysfunction of T cells can also cause poor response to CAR T therapy, and being unable to collect enough T cells can also negatively affect the impact of CAR T products; however, these factors are not considered key mechanisms for resistance to CAR T-cell therapy. As such, early collection of T-cells in high-risk patients with DLBCL is one strategy to ensure enough T cells are available when needed. Partial response or relapse after CAR T therapy should prompt third-line therapy, such as alternative systemic therapy not previously given, clinical trial, palliative involved-site radiation therapy, or best supportive care. Learn more about relapsed or refractory DLBCL.

What to know about the new ‘Nimbus' COVID variant
What to know about the new ‘Nimbus' COVID variant

Yahoo

time5 hours ago

  • Yahoo

What to know about the new ‘Nimbus' COVID variant

The World Health Organization (WHO) is keeping an eye on a new COVID-19 variant called NB.1.8.1, or 'Nimbus,' that has spread across Europe, the Americas and the Western Pacific. Nimbus is a descendant of the Omicron variant of the virus and was first identified in late January. Its spike mutations appear to make it more transmissible than other COVID-19 variants, according to the WHO. Spike mutations refer to changes in spike proteins, which sit on the surface of the virus and help it enter healthy cells. While it is spreading in the U.S. and Canada, along with 20 other countries, it does not appear to be driving an increase in sickness or hospitalization. In April, NB.1.8.1 sequences made up 10.7 percent of all submitted sequences from confirmed COVID infections, up from 2.5 percent a month earlier, according to a risk evaluation released by the WHO. The WHO last month deemed NB.1.8.1 a variant 'under monitoring.' Here's what to know about the variant. Most cases of COVID-19 in the U.S. still stem from the LP.8.1 strain, another Omicron descendant. But it looks like NB.1.8.1 might soon replace it as the more common strain, according to data from the Centers for Disease Control and Prevention (CDC). The CDC estimates that 37 percent of COVID-19 cases in the U.S. stem from the NB.1.8.1 variant, while 38 percent are a result from an infection of the LP.8.1 strain of the disease. At the end of May, the agency estimated the NB.1.8.1 variant caused about 15 percent of all COVID-19 cases. But the agency notes on its website that due to low numbers of virus sequences being reported, precision in the most recent reporting period is low. The NB.1.8.1 variant has been found in at least 13 states, according to Today, which cited data from the Global Initiative on Sharing All Influenza Data (GISAID) database. Those states are: California, New York, New Jersey, Maryland, Arizona, Illinois, Hawaii, Massachusetts, Ohio, Rhode Island, Vermont, Virginia and Washington. The available data on 'Nimbus' suggests it poses a low global threat and that existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization, according to the WHO. 'Currently approved COVID-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease,' the WHO's risk evaluation reads. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation.' Lionel Gresh, an international consultant at the WHO, told The Hill that many new cases in Canada are likely linked to the NB.1.8.1 variant, but that there has not been any major changes in the country in terms of cases, hospitalizations, ICU admissions or deaths linked to COVID-19. Symptoms of NB.1.8.1 seem to be similar to those associated with other Omicron variants, according to Gresh. Some common COVID-19 symptoms include cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting, and a new loss of smell or taste, according to the CDC. 'We should be as concerned about [NB.1.8.1] as we are concerned for COVID in general,' Gresh said. 'Not more, not less.' Some recent COVID-19 patients have reported experiencing something called 'razor blade throat,' according to Salon. But it is unclear if that symptom is connected to one of the COVID variants or another respiratory illness circulating, Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, told Salon. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store